Head-To-Head Review: Recursion Pharmaceuticals (NASDAQ:RXRX) & NewAmsterdam Pharma (NASDAQ:NAMSW)

NewAmsterdam Pharma (NASDAQ:NAMSW) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Profitability

This table compares NewAmsterdam Pharma and Recursion Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	N/A	N/A	N/A
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

Valuation and Earnings

This table compares NewAmsterdam Pharma and Recursion Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$7.12 million	N/A	N/A	N/A	N/A
Recursion Pharmaceuticals	$74.68 million	23.49	-$644.76 million	($1.04)	-3.18

NewAmsterdam Pharma has higher earnings, but lower revenue than Recursion Pharmaceuticals.

Insider & Institutional Ownership

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for NewAmsterdam Pharma and Recursion Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0	0	0	0	0.00
Recursion Pharmaceuticals	1	2	2	0	2.20

Recursion Pharmaceuticals has a consensus price target of $8.10, indicating a potential upside of 144.71%. Given Recursion Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than NewAmsterdam Pharma.

Summary

Recursion Pharmaceuticals beats NewAmsterdam Pharma on 6 of the 9 factors compared between the two stocks.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.